BioMed Valley Discoveries

BioMed Valley Discoveries is a privately held, clinical-stage biotech with a novel operational and funding structure, wholly owned by a supporting organization of the non-profit Stowers Institute for Medical Research. This setup provides stable capital, allowing the company to pursue risk-tolerant, early-stage translational and clinical programs in oncology and other serious diseases. Its most advanced candidate is ulixertinib, a first-in-class ERK1/2 inhibitor, with a Phase 2 trial ongoing in histiocytosis and other MAPK-driven cancers. The company's strategy is to de-risk assets through clinical proof-of-concept and then partner them for later-stage development and commercialization.

A unique business and development model centered on risk-tolerant sourcing, deep scientific de-risking, and an extensive collaborator network to advance early-stage assets to clinical proof-of-concept for partnership.

BVD competes in the crowded oncology field, particularly against other companies developing MAPK pathway inhibitors (including ERK inhibitors) and next-generation Antibody-Drug Conjugates (ADCs). Its differentiation lies not in head-to-head commercial competition, but in its ability to take on higher-risk, earlier-stage science that others may bypass.